莫西沙星短程治疗慢性阻塞性肺疾病急性加重期的临床评价

Clinical evaluation of moxifloxacin in the short-term treatment of acute exacerbation chronic obstructive pulmonary disease

目的探讨莫西沙星短程治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及安全性。方法 60例AECOPD患者随机分成试验组和对照组各30例,试验组采用莫西沙星治疗,疗程为5d;对照组给予左氧氟沙星治疗,疗程为10d。观察2组临床疗效。结果试验组有效率和细菌清除率高于对照组,差异均有统计学意义(P<0.05)。结论莫西沙星短程治疗对AECOPD有良好的治疗效果,无明显不良反应,可作为AECOPD的一线治疗药物。

Objective To evaluate the efficacy and safety of intravenous moxifloxacin in the short-term treatment of lower respiratory tract infection with acute exacerbation chronic obstructive pulmonary disease（AECOPD）.Methods 60 patients with AECOPD were randomly into test group and control group,30 cases of each.Patients were treated with moxifloxacin for 5 days in the test group.Levofloxacin was given for 10 days in the control group,observed the clinical effect of the two groups.Results The effective rate and bacterial eradication rates were higher than the control group,there were statistically significant differences between the two groups（P0.05）.Conclusion Moxifloxacin is effective and safe in the treatment of AECOPD.